
ACHV Stock Forecast & Price Target
ACHV Analyst Ratings
Bulls say
Achieve Life Sciences is a late-stage clinical specialty pharmaceutical company with a strong focus on addressing the nicotine dependence epidemic through the development and commercialization of cytisinicline, a naturally occurring alkaloid. The recent Complete Response Letter (CRL) for cytisinicline in smoking cessation, which did not raise any new clinical concerns, provides a more defined regulatory roadmap and supports our positive thesis on the stock. We believe that the company's plan to resubmit the NDA in 4Q26 and potential 1H27 launch, along with its progress in transitioning to a new commercial manufacturing partner, bode well for the success of this product. Risks include 1) Commercial execution risk, 2) Clinical trial risk, 3) Regulatory risk, 4) Financing risk, and 5) Risk of a required partner controlling commercialization efforts.
Bears say
Achieve Life Sciences is currently facing a delay in their PDUFA date, scheduled for June 2026, due to technology transfer completion to Adare Pharma Solutions. This delay has caused the market to price in a potential CMC-only CRL and shift the focus to a resubmission in 4Q26 and potential launch in 1H27. While this presents a favorable risk-reward scenario with potential upside upon approval, the company's sole focus on nicotine dependence and its limited market penetration may pose challenges in the highly competitive smoking cessation market. The financials also show a decline in revenue from $0.20 million in 2019 to $0.01 million in 2020, raising concerns about the company's financial stability.
This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
ACHV Analyst Forecast & Price Prediction
Start investing in ACHV
Order type
Buy in
Order amount
Est. shares
0 shares